Grundlagen der Tumorschmerztherapie bei Kindern und Jugendlichen

  • R. Sittl
  • H. Huber
  • N. Griessinger
  • R. Richter
  • J. Sorge
Conference paper


To be successful, any pain therapy must be preceded by a precise pain history and a physical examination, and account must be taken of psychic influences that might be factors in the experience of pain. It is crucial for a positive result of medicamentous pain therapy that the patient and parents receive detailed explanation of the procedures to be applied and of the necessity for preventive treatment, preferably using sustained release preparations given by mouth according to a predetermined time-schedule. The intensity and nature of the pain felt and the effects and side-effects of the therapy must be regularly recorded.

The guideline for medicamentous therapy for tumour pain is the WHO’s graduated schedule, which is also the basis of the design for pain therapy from the Working Group on Pain within the Society for Paediatric Oncology (Konzept zur Schmerztherapie der Arbeitsgruppe Schmerz der Gesellschaft für Pädiatrische Onkologie). The WHO schedule begins with the non-narcotic analgesics that inhibit prostaglandin synthesis for level 1. Preparations of this type often have a very good effect, especially in the case of nociceptor pain (e.g. those arising from bone metastases). Profens (e.g. ibuprofen) and arylacetic acid (e.g. diclofenac) are generally better tolerated than acetylsalicylic acid. Dipyrone is also suitable for use in children from the third month of life onward. It is important to apply a sufficiently high dosage, although when paracetamol is given this should not exceed 90 mg/kg body weight per day, as otherwise there is a danger of toxic liver damage. (The appropriate antidote is acetylcysteine.) If these analgesics do not afford adequate pain relief it is necessary to proceed to stage 2, in which they are combined with weak opioids (e.g. dihydrocodeine or codeine). In stage 3, strong opioids are used instead of weak ones. Preparations suitable for combination with opioids in children are dipyrone (5–15 mg per kg body weight) and paracetamol (10–15 mg per kg body weight), either of which can be given every 4–6 h.

The most important tenet is that the analgesics must be given not “as needed”, but according to a precisely worked out time-schedule designed so that each dose is administered in anticipation of the imminent onset of pain, before the pain is in fact perceived. The preparations of choice are sustained release preparations of drugs that can be given by mouth. If oral administration is no longer possible, portable infusion pumps can be used for continuous administration of opioids by the subcutaneous or the intravenous route.

In some pain syndromes or in the presence of other symptoms associated with the basic tumour illness, it may be that other drugs are also indicated (e.g. neuroleptics, sedatives and hypnotics, tricyclic antidepressants, anticonvulsive agents, spasmolytics); these should be given as adjuvant agents and not on any account as a substitute for opioids.

Various requirements and demands must be fulfilled if tumour pain in children is to be successfully treated: interdisciplinary planning of the therapy, prompt administration and adequate dosage of opioids, preventive therapy for side-effects, consistent documentation of effects and side-effects, and detailed discussion with parents and children.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Anand KJS, Hickey PR (1987) Pain and its effects in the human neonate and fetus. N Engl J Med 317: 1321–1329PubMedCrossRefGoogle Scholar
  2. 2.
    Amer S (1982) The role of nerve blocks in the treatment of cancer pain. Acta Anaesthesiol Scand 74 [Suppl]: 104Google Scholar
  3. 3.
    Berde CB, Fischel N, Filardi PJ, Coe CS, Grier HE, Bernstein SC (1989) Caudal epidural morphine for an infant with advanced neuroblastoma: report of a case. Pain 36: 219–233PubMedCrossRefGoogle Scholar
  4. 4.
    Berde CB (1990) The treatment of pain in children. Pain [Suppl5]: 3–4CrossRefGoogle Scholar
  5. 5.
    Cornaglia C, Massimo L, Haupt R, Melodia A, Sizemore W, Benedetti C (1984) Incidence of pain in children with neoplastic diseases. Pain [Suppl2]: 28CrossRefGoogle Scholar
  6. 6.
    Eland JM, Anderson JE (1977) The experience of pain in children. In: Jacox A (ed): A source book for nurses and other health professionals. Little Brown, BostonGoogle Scholar
  7. 7.
    Maunuksela EL, Suutarinen T (1989) Besonderheiten der Schmerzbehandlung im Kindesalter. Anästh Intensivmed 30: 103–106Google Scholar
  8. 8.
    McGrath PA, Hillier LM (1989) The enigma of pain in children: an overview. Pediatrician 16: 6–15PubMedGoogle Scholar
  9. 9.
    Miser AW, Miser JS, Clark BS (1980) Continuous intravenous infusion of morphine sulfate for control of severe pain in children with terminal cancer. J Pediatrics 96: 930–932CrossRefGoogle Scholar
  10. 10.
    Miser AW, Dothage JA, Wesley RA, Miser JS (1987) The prevalence of pain in a pediatric and young adult cancer population. Pain 29: 73–83PubMedCrossRefGoogle Scholar
  11. 11.
    Miser AW, McCalla J, Dothage JA (1987) Pain as a presenting symptom in children and young adolescents with newly diagnosed malignancy. Pain 29: 85–90PubMedCrossRefGoogle Scholar
  12. 12.
    Richter R, Sittl R, Beck JD, Kamp HD (1989) Zur Notwendigkeit einer standardisierten Schmerztherapie bei pädiatrisch onkologischen Patienten. Klin Pädiatr 201: 330–332PubMedCrossRefGoogle Scholar
  13. 13.
    Schechter NL, Allen DA, Hanson K (1986) Status of pediatric pain control: a comparison of hospital analgesic usage in children and adults. Pediatrics 77: 11–15PubMedGoogle Scholar
  14. 14.
    Schechter NL (1989) Annotation–management of pain in children. Aust Paediatr J 25: 1–2PubMedGoogle Scholar
  15. 15.
    Sittl R, Richter R (1991) Tumorschmerztherapie bei Kindern und Jugendlichen mit Morphin. Anaesthesist 40: 96–99PubMedGoogle Scholar
  16. 16.
    Sorge J (1989) Einsatz von starken Opioiden in der Behandlung des Krebsschmerzes bei Erwachsenen und Kindern. Klin Pädiatr 201: 333–336PubMedCrossRefGoogle Scholar
  17. 17.
    Sorge J, Lehmkuhl C, Lohse K, Herrmann H, Pichlmayr I (1990) Langzeittherapie von Tumorschmerzen mit Morphin-retard-Tabletten. Med Klin 85: 523–528Google Scholar
  18. 18.
    Tyler DC, Kranc EJ (1989) Epidural opioids in children. J Pediatr Surg 24: 469–473PubMedCrossRefGoogle Scholar
  19. 19.
    World Health Organization (1986) Cancer pain relief. Office of Publications, WHO, GenfGoogle Scholar
  20. 20.
    Yaster M, Deshpande JK (1988) Management of pediatric pain with opioid analgesics. J Pediatr 113: 421–429PubMedCrossRefGoogle Scholar
  21. 21.
    Zeltzer LK, Zeltzer PM (1989) Clinical assessment and pharmacologic treatment of pain in children: cancer as a model for the management of chronic or persistent pain. Pediatrician 16: 64–70PubMedGoogle Scholar
  22. 22.
    Zimmermann M (1989) Neuro-Psychophysiologie des Schmerzes bei Kindern. Schmerz 3: 73–79PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • R. Sittl
    • 1
  • H. Huber
    • 1
  • N. Griessinger
    • 1
  • R. Richter
    • 1
  • J. Sorge
    • 1
  1. 1.Institut für AnästhesiologieUniversitätskliniken Erlangen-NürnbergErlangenDeutschland

Personalised recommendations